1. Home
  2. EQBK vs PHAT Comparison

EQBK vs PHAT Comparison

Compare EQBK & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equity Bancshares Inc.

EQBK

Equity Bancshares Inc.

HOLD

Current Price

$47.30

Market Cap

989.1M

Sector

Finance

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$10.89

Market Cap

894.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQBK
PHAT
Founded
2002
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
989.1M
894.0M
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
EQBK
PHAT
Price
$47.30
$10.89
Analyst Decision
Hold
Strong Buy
Analyst Count
3
6
Target Price
$51.33
$19.83
AVG Volume (30 Days)
83.6K
1.0M
Earning Date
04-14-2026
04-30-2026
Dividend Yield
1.59%
N/A
EPS Growth
N/A
42.72
EPS
0.80
N/A
Revenue
N/A
$175,110,000.00
Revenue This Year
$74.58
$93.04
Revenue Next Year
$5.11
$58.91
P/E Ratio
$58.64
N/A
Revenue Growth
N/A
216.93
52 Week Low
$36.04
$7.61
52 Week High
$50.07
$18.31

Technical Indicators

Market Signals
Indicator
EQBK
PHAT
Relative Strength Index (RSI) 56.79 52.16
Support Level $44.45 $10.92
Resistance Level $48.58 $12.99
Average True Range (ATR) 0.95 0.58
MACD -0.04 0.16
Stochastic Oscillator 59.47 75.39

Price Performance

Historical Comparison
EQBK
PHAT

About EQBK Equity Bancshares Inc.

Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 77 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: